MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Venture Capital: Risk Capital_Angel, Venture, Sovereign Wealth Investor Companies & Organizations
Portfolio Companies: Laidlaw
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), formerly, pSivida (NASDAQ:PSDV)*
Organization & Developments: pSivida
Parents
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), formerly, pSivida (NASDAQ:PSDV)*
Children
*BioSilicon™ is a biodegradable, bioactive and biocompatible form of silicon, which disolves in the body to become silicic acid, the most common form of which is found in everyday foodstuffs.
*Developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN® for the treatment of Diabetic Macular Edema
*Its core focus the development of nano-structured porous silicon (BioSilicon™) for slow release controlled drug delivery and brachytherapy.
*pSivida is a world leader in the development of tiny drug delivery products that are administered by implantation, injection or insertion and provide sustained release of drugs on a controlled and level basis for months or years
2016: 2 Small Biotech Stocks Poised For Substantial Upside - pSivida Corp. (NASDAQ:PSDV)
2016: Biotech Daily Digest: Exelixis Continues Its Rampage, Spotlight On pSivida
2016: PSivida: ~$4 Ocular Concern Is 'Looking Good' - pSivida Corp. (NASDAQ:PSDV)
2017: pSivida Undervalued With Final Phase III Durasert Data Imminent - pSivida Corp. (NASDAQ:PSDV)
2017: Second late-stage uveitis study of pSivida's Durasert successful; shares ahead 13% premarket - pSivida Corp. (NASDAQ:PSDV)
2018: EyePoint: Shouldn't The Market Be More Enthusiastic? - EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
2018: Reader Inquiry: EyePoint Pharmaceuticals Is On A Tear, What's Going On?_seekingalpha.com
2019: EyePoint Pharmaceuticals Is Eyeing 2 Big Market Opportunities_seekingalpha.com
2019: EyePoint Pharmaceuticals: Poised For Growth In 2019_seekingalpha.com
2019: Why Investors Have Underestimated EyePoint's Dexycu And Yutiq Growth Potential Since Launch_seekingalpha.com
2022: Eyepoint Pharmaceuticals (EYPT) Investor Presentation - Slideshow_ seekingalpha.com
2023: Countdown To Clarity: EyePoint's December Data Delivery
2023: EyePoint Pharmaceuticals Soaring On Wet AMD Study Results: Durasert Looks Real Deal_seekingalpha
2023: EyePoint Pharmaceuticals’ stock soars 212% after company announces positive data for macular degeneration treatment
2024: EyePoint dinged with FDA warning letter over manufacturing shortfalls tied to eye implant
2024: EyePoint Is Betting The Bank On EYP-1901
2024: EyePoint Pharmaceuticals Advances in Retinal Therapeutics_www.tipranks.com
2024: EyePoint Pharmaceuticals, Inc. - EYPT STOCK NEWS _ EYPT
2024: EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time
2024: EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity
2025: EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026
2025: EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival
2026: EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
Jumps
*Key People: pSivida
Finance & Acquisition: pSivida